Details of the Drug Combination

General Information of Drug Combination (ID: DCKW0JR)

Drug Combination Name
Rituximab ACTR087
Indication
Disease Entry Status REF
B-cell lymphoma Phase 1 [1]
Component Drugs Rituximab   DM1YVZT ACTR087   DMW9GX0
Antibody N.A.

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Rituximab
Disease Entry ICD 11 Status REF
Central nervous system non-hodgkin lymphoma N.A. Approved [2]
Eosinophilic granulomatosis with polyangiitis 4A44.A2 Approved [3]
Hepatosplenic T-cell lymphoma N.A. Approved [4]
Idiopathic thrombocytopenic purpura 3B64.10 Approved [5]
Large granular lymphocytic leukemia 2A90.1 Approved [6]
Leukemia N.A. Approved [7]
Lupus nephritis 4A40.0Y Approved [8]
Lymphoproliferative syndrome N.A. Approved [9]
Lymphosarcoma N.A. Approved [10]
MALT lymphoma N.A. Approved [11]
Nodal marginal zone lymphoma 2A85.0 Approved [12]
Non-hodgkin lymphoma 2B33.5 Approved [13]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified N.A. Approved [14]
Prolymphocytic leukaemia 2A82.1 Approved [15]
Recurrent adult burkitt lymphoma 2A85.6 Approved [16]
Small intestine lymphoma N.A. Approved [17]
Small lymphocytic lymphoma 2A82.0 Approved [18]
Splenic marginal zone lymphoma N.A. Approved [19]
Testicular lymphoma N.A. Approved [20]
Thrombotic thrombocytopenic purpura 3B64.14 Approved [21]
Waldenstrom macroglobulinemia 2A85.4 Approved [22]
Pemphigus vulgaris EB40 Phase 3 [23]
Haematological malignancy 2B33.Y Phase 1 [24]
B-cell neoplasm N.A. Investigative [25]
Rituximab Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Leukocyte surface antigen Leu-16 (CD20) TTUE541 CD20_HUMAN . [27]
Leukocyte surface antigen Leu-16 (CD20) TTUE541 CD20_HUMAN . [28]
------------------------------------------------------------------------------------
Rituximab Interacts with 4 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Increases ADR [29]
Low affinity immunoglobulin gamma Fc region receptor III-A (FCGR3A) OTOWXCF3 FCG3A_HUMAN Increases Response [30]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases ADR [29]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Increases ADR [29]
------------------------------------------------------------------------------------
Indication(s) of ACTR087
Disease Entry ICD 11 Status REF
Non-hodgkin lymphoma 2B33.5 Phase 1 [26]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 How we treat primary central nervous system lymphoma. ESMO Open. 2021 Aug;6(4):100213.
3 Update on eosinophilic granulomatosis with polyangiitis. Allergol Int. 2019 Oct;68(4):430-436.
4 Coexistent hairy cell leukaemia and hepatosplenic T-cell lymphoma: a case report. Diagn Pathol. 2014 Mar 12;9:58.
5 Idiopathic thrombocytopenic purpura (ITP) - new era for an old disease. Rom J Intern Med. 2019 Dec 1;57(4):273-283.
6 Rituximab for rheumatoid arthritis-associated large granular lymphocytic leukemia, a retrospective case series. Semin Arthritis Rheum. 2020 Oct;50(5):1109-1113.
7 Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006 Apr 1;106(7):1569-80.
8 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020 Jun;79(6):713-723.
9 Autoimmune lymphoproliferative syndrome: A disorder of immune dysregulation. Autoimmun Rev. 2023 Nov;22(11):103442.
10 Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 1999;18(4):465-71.
11 Diagnosis and Treatment for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. J Clin Med. 2022 Dec 23;12(1):120.
12 Nodal marginal zone lymphoma. Leuk Lymphoma. 2014 Jun;55(6):1240-50.
13 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
14 A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
15 B and T cell prolymphocytic leukaemia. Best Pract Res Clin Haematol. 2019 Sep;32(3):217-228.
16 Burkitt lymphoma - no impact of HIV status on outcomes with rituximab-based chemoimmunotherapy. Leuk Lymphoma. 2023 Mar;64(3):586-596.
17 Metachronous primary cancer of the tongue and malignant lymphoma of the small intestine: A case report. Medicine (Baltimore). 2021 Feb 19;100(7):e24806.
18 Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022 Aug;23(8):1031-1043.
19 Treatment of splenic marginal zone lymphoma. Best Pract Res Clin Haematol. 2017 Mar-Jun;30(1-2):139-148.
20 First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011 Jul 10;29(20):2766-72.
21 Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. J Clin Med. 2021 Feb 2;10(3):536.
22 Waldenstr?m macroglobulinemia: 2023 update on diagnosis, risk stratification, and management. Am J Hematol. 2023 Feb;98(2):348-358.
23 ClinicalTrials.gov (NCT02383589) A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients With Pemphigus Vulgaris. U.S. National Institutes of Health.
24 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6780).
25 Diffuse Large B-Cell Lymphoma and Related Entities. Dtsch Arztebl Int. 2023 Apr 28;120(17):289-296.
26 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
27 [Contribution of radioimmunotherapy to the treatment of lymphoma]. Ann Pharm Fr. 2008 Nov-Dec;66(5-6):300-8.
28 Clinical pipeline report, company report or official report of Genentech (2009).
29 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
30 FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood. 2006 Oct 15;108(8):2720-5. doi: 10.1182/blood-2006-01-009480. Epub 2006 Apr 11.